Compare Citius Pharmaceuticals Inc (CTXR) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Wahed FTSE USA Shariah ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Wahed FTSE USA Shariah ETF trades at $71.3. The key difference: Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | HLAL | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $73.60 |
52-Week Low | $0.53 | $53.83 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
HLAL trades at $71.08, down 1.34% today. The technical outlook is bullish based on moving averages, with oscillators neutral. Key support sits at $71 and resistance at $72. A dividend of $0.02 is scheduled for June 2026. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
The stock's near-term trajectory hinges on upcoming earnings and broader market trends. Risks include lack of recent financial disclosures and potential volatility. Upside depends on positive fundamental developments and sustained technical momentum amid neutral sentiment indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →
